Xilio Therapeutics, Inc. Comprehensive Income
Xilio Therapeutics, Inc. (XLO) reported Comprehensive Income of -$6.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$6.37M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$9.53M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $10.36M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$16.29M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$35.04M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$58.24M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$76.40M.
- Xilio Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$88.22M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.37M 10-Q · filed 2026-08-12 | -$15.90M 10-Q · filed 2026-08-12 | -$5.54M derived: sum of 3 quarters · filed 2026-08-12 | -$21.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$9.53M 10-Q · filed 2026-05-12 | $831.00K derived: sum of 2 quarters · filed 2026-05-12 | -$15.46M derived: sum of 3 quarters · filed 2026-05-12 | -$31.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$5.93M derived: sum of 2 quarters · filed 2026-03-23 | -$21.77M derived: sum of 3 quarters · filed 2026-08-12 | -$35.04M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$16.29M 10-Q · filed 2025-11-13 | -$32.13M derived: sum of 2 quarters · filed 2026-08-12 | -$45.40M 10-Q · filed 2025-11-13 | -$58.49M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$15.84M 10-Q · filed 2026-08-12 | -$29.11M 10-Q · filed 2026-08-12 | -$42.20M derived: sum of 3 quarters · filed 2026-08-12 | -$56.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$13.27M 10-Q · filed 2026-05-12 | -$26.36M derived: sum of 2 quarters · filed 2026-05-12 | -$40.38M derived: sum of 3 quarters · filed 2026-05-12 | -$54.30M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$13.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$27.11M derived: sum of 2 quarters · filed 2026-03-23 | -$41.04M derived: sum of 3 quarters · filed 2026-03-23 | -$58.24M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$14.02M 10-Q · filed 2025-11-13 | -$27.95M derived: sum of 2 quarters · filed 2025-11-13 | -$45.15M 10-Q · filed 2025-11-13 | -$62.80M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$13.93M 10-Q · filed 2025-08-14 | -$31.13M 10-Q · filed 2025-08-14 | -$48.78M derived: sum of 3 quarters · filed 2025-08-14 | -$65.53M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$17.20M 10-Q · filed 2025-05-08 | -$34.86M derived: sum of 2 quarters · filed 2025-05-08 | -$51.61M derived: sum of 3 quarters · filed 2025-05-08 | -$70.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$17.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$34.40M derived: sum of 2 quarters · filed 2025-03-11 | -$53.76M derived: sum of 3 quarters · filed 2025-03-11 | -$76.40M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$16.75M 10-Q · filed 2024-11-07 | -$36.10M derived: sum of 2 quarters · filed 2024-11-07 | -$58.75M 10-Q · filed 2024-11-07 | -$81.22M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$19.36M 10-Q · filed 2024-08-08 | -$42.00M 10-Q · filed 2024-08-08 | -$64.47M derived: sum of 3 quarters · filed 2024-08-08 | -$84.26M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$22.65M 10-Q · filed 2024-05-14 | -$45.11M derived: sum of 2 quarters · filed 2024-05-14 | -$64.90M derived: sum of 3 quarters · filed 2024-05-14 | -$89.52M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$22.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$42.26M derived: sum of 2 quarters · filed 2024-04-01 | -$66.87M derived: sum of 3 quarters · filed 2024-04-01 | -$88.22M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$19.79M 10-Q · filed 2023-11-09 | -$44.40M derived: sum of 2 quarters · filed 2023-11-09 | -$65.76M 10-Q · filed 2023-11-09 | -$85.46M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$24.61M 10-Q · filed 2023-08-14 | -$45.97M 10-Q · filed 2023-08-14 | -$65.67M derived: sum of 3 quarters · filed 2023-08-14 | -$81.92M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$21.35M 10-Q · filed 2023-05-09 | -$41.05M derived: sum of 2 quarters · filed 2023-05-09 | -$57.30M derived: sum of 3 quarters · filed 2023-05-09 | -$80.49M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$35.95M derived: sum of 2 quarters · filed 2023-03-02 | -$59.13M derived: sum of 3 quarters · filed 2023-03-02 | -$75.80M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$16.25M 10-Q · filed 2022-11-09 | -$39.43M derived: sum of 2 quarters · filed 2022-11-09 | -$56.10M 10-Q · filed 2022-11-09 | -$76.87M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$23.18M 10-Q · filed 2022-08-09 | -$39.85M 10-Q · filed 2022-08-09 | -$60.62M derived: sum of 3 quarters · filed 2022-08-09 | -$75.44M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$16.67M 10-Q · filed 2022-05-12 | -$37.44M derived: sum of 2 quarters · filed 2022-05-12 | -$52.26M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$20.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$35.59M derived: sum of 2 quarters · filed 2022-03-01 | -$55.22M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$14.82M 10-Q · filed 2021-12-02 | -$34.45M 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |